Edition:
United States

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,558.00GBp
19 Jul 2018
Change (% chg)

-- (--)
Prev Close
1,558.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
8,760,640
52-wk High
1,632.00
52-wk Low
1,235.20

Latest Key Developments (Source: Significant Developments)

Novartis Completes Sale Of Stake In Consumer Healthcare JV To GSK
Friday, 1 Jun 2018 08:00am EDT 

June 1 (Reuters) - NOVARTIS AG ::COMPLETES SALE OF STAKE IN CONSUMER HEALTHCARE JOINT VENTURE TO GSK FOR USD13.0 BILLION.  Full Article

Neomed-Labs Extends Strategic Deal With GSK
Thursday, 31 May 2018 06:00am EDT 

May 31 (Reuters) - GlaxoSmithKline PLC ::NEOMED-LABS SAYS EXTENSION OF STRATEGIC DEAL WITH GSK.  Full Article

GlaxoSmithKline Receives US Approval Of Arnuity Ellipta For Use In Children From 5 Years Old Who Suffer From Asthma
Monday, 21 May 2018 11:38am EDT 

May 21 (Reuters) - GlaxoSmithKline PLC ::GSK RECEIVES US APPROVAL OF ARNUITY ELLIPTA FOR USE IN CHILDREN FROM 5 YEARS OLD WHO SUFFER FROM ASTHMA.RECEIVED APPROVAL FROM US FDA FOR USE OF ARNUITY ELLIPTA (FLUTICASONE FUROATE) FOR MAINTENANCE TREATMENT OF ASTHMA IN CHILDREN FROM AS YOUNG AS 5 YEARS.  Full Article

U.S. FDA Alerts Of Neural Tube Birth Defects Cases Reported In Babies Born To Women Treated With Dolutegravir
Friday, 18 May 2018 12:45pm EDT 

May 18 (Reuters) - U.S. Food and Drug Administration::U.S. FDA SAYS ALERTING PUBLIC TO SERIOUS CASES OF NEURAL TUBE BIRTH DEFECTS REPORTED IN BABIES BORN TO WOMEN TREATED WITH DOLUTEGRAVIR USED TO TREAT HIV.SAYS PRELIM RESULTS FROM ONGOING STUDY FOUND WOMEN GETTING DOLUTEGRAVIR AT TIME OF BECOMING PREGNANT/EARLY IN FIRST TRIMESTER APPEAR AT HIGHER RISK FOR DEFECTS.SAYS TO DATE, IN STUDY, THERE ARE NO REPORTED CASES OF BABIES BORN WITH NEURAL TUBE DEFECTS TO WOMEN STARTING DOLUTEGRAVIR LATER IN PREGNANCY.  Full Article

Theravance Biopharma Says FDA Has Approved An Expanded Indication For Trelegy Ellipta
Wednesday, 25 Apr 2018 08:30am EDT 

April 25 (Reuters) - Theravance Biopharma Inc ::THERAVANCE BIOPHARMA HIGHLIGHTS APPROVAL OF EXPANDED INDICATION IN THE US FOR ONCE-DAILY TRELEGY ELLIPTA FOR TREATMENT OF COPD PATIENTS.THERAVANCE BIOPHARMA INC - U.S. FDA HAS APPROVED AN EXPANDED INDICATION FOR TRELEGY ELLIPTA.THERAVANCE BIOPHARMA INC - EXPANDED APPROVAL IN U.S. ALLOWS TRELEGY ELLIPTA TO BE USED AS A TREATMENT FOR A BROADER POPULATION OF COPD PATIENTS.  Full Article

GSK Names Kevin Sin As Worldwide Business Development Head For R&D
Wednesday, 18 Apr 2018 09:06am EDT 

April 18 (Reuters) - GlaxoSmithKline PLC ::APPOINTS KEVIN SIN AS NEW SENIOR VP AND HEAD OF WORLDWIDE BUSINESS DEVELOPMENT FOR RESEARCH AND DEVELOPMENT.  Full Article

Novartis AG CEO Says Believes Avexis SMA Medicine Has Multi-Billion Dollar Peak Sales Potential
Monday, 9 Apr 2018 02:43am EDT 

April 9 (Reuters) - Novartis Ag ::CEO SAYS PLANS TO USE PORTION OF GSK CONSUMER JOINT VENTURE TRANSACTION PROCEEDS TO BUY AVEXIS.CEO SAYS BELIEVES AVEXIS MAIN SMA MEDICINE HAS MULTI-BILLION DOLLAR PEAK SALES POTENTIAL.  Full Article

GlaxoSmithKline Says Gets Positive CHMP Opinion For Juluca In Europe
Friday, 23 Mar 2018 07:21am EDT 

March 23 (Reuters) - GlaxoSmithKline Plc ::VIIV - CHMP POSITIVE OPINION FOR JULUCA IN EUROPE.‍VIIV HEALTHCARE GAINS CHMP POSITIVE OPINION FOR JULUCA (DOLUTEGRAVIR/RILPIVIRINE) IN EUROPE​.FINAL EC DECISION ON EUROPEAN APPROVAL FOR DOLUTEGRAVIR/RILPIVIRINE IS ANTICIPATED TOWARDS END OF Q2 OF 2018.  Full Article

GSK did not put in final bid for Pfizer consumer unit - source
Friday, 23 Mar 2018 06:13am EDT 

March 23 (Reuters) - Glaxosmithkline Plc GSK.L::GLAXOSMITHKLINE DID NOT PUT IN A FINAL BID FOR PFIZER'S CONSUMER HEALTHCARE UNIT - SOURCE FAMILIAR WITH SITUATION.  Full Article

Pfizer says continues to evaluate options for consumer health
Friday, 23 Mar 2018 04:54am EDT 

March 23 (Reuters) - Pfizer Inc ::PFIZER SAYS CONTINUES TO EVALUATE POTENTIAL STRATEGIC ALTERNATIVES FOR THE CONSUMER HEALTHCARE BUSINESS, INCLUDING A SPIN-OFF,SALE OR OTHER TRANSACTION, AND PFIZER ULTIMATELY RETAINING THE BUSINESS..PFIZER SAYS HAS NOT YET MADE A DECISION, BUT CONTINUES TO EXPECT ONE IN 2018.  Full Article

Photo

Clamor for GSK shingles shot points to bigger profits

LONDON GlaxoSmithKline is facing "unprecedented" demand for its new shingles vaccine Shingrix, suggesting the product could be a bigger money-spinner than the company and analysts initially thought.